TP53 and familial pancreatic carcinoma: The in vitro experiments carried out on the human pancreatic cancer cell line (PNAC1) clearly demonstrated that the loading of drug (ICA) into a bilosomes-MEL carrier (ICA-BM) significantly improved all the parameters related to the anticancer efficacy of the ICA towards cancer cells, including the decreased IC50, the enhanced anti-proliferative and pro-apoptotic/necrotic activities, as well as the augmented caspase-3 and p53 protein levels.